Results 51 to 60 of about 15,419 (219)

Executive Summary: Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease in China

Kidney Diseases, 2020
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, with a prevalence of 1/2,500–1/1,000, and it affects 1.25 million people in China.
Chang-Lin Mei, Cheng Xue, Sheng-Qiang Yu, Bing Dai, Jiang-Hua Chen, Ying Li, Li-Meng Chen, Zhang-Suo Liu, Yong-Gui Wu, Zhao Hu, Yan Zha, Hong Liu, Yong-Ze Zhuang, Chun Zhang, Xiang-Cheng Xiao, Yue Wang, Gui-Sen Li, Yi-Yi Ma, Lin Li   +18 more
doaj   +1 more source

Characteristics of Patients with End-Stage Kidney Disease in ADPKD

Kidney International Reports, 2020
Introduction Cystic expansion damaging the parenchyma is thought to lead to end-stage kidney disease (ESKD) in autosomal dominant polycystic kidney disease (ADPKD).
Shehbaz Shukoor, Lisa E. Vaughan, Marie E. Edwards, S. Lavu, T. Kline, Sarah R. Senum, Yaman G. Mkhaimer, G. Zaatari, M. Irazabal, Reem M. Neal, M. Hogan, Ziad M. Zoghby, P. Harris, V. Torres, F. Chebib   +14 more
semanticscholar   +1 more source

TAMEing ADPKD with metformin: safe and effective?

Kidney International, 2021
The biguanide metformin has been safely and widely used in the treatment of type 2 diabetes mellitus for decades. Preclinical studies have suggested that it may have a role in slowing disease progression in autosomal dominant polycystic kidney disease. In this issue, Perrone et al.
Ong, A.C.M., Gansevoort, R.T.
openaire   +3 more sources

Biomarkers of Kidney Disease Progression in ADPKD

Kidney International Reports
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disorder and the fourth leading cause of kidney failure (KF) in adults.
Ahmad Ghanem, Abdul Hamid Borghol, Fadi George Munairdjy Debeh, Stefan Paul, Bassel Alkhatib, Peter C. Harris, P. Garimella, Christian Hanna, Timothy L. Kline, N. Dahl, F. Chebib   +10 more
semanticscholar   +1 more source

Acute Kidney Injury in ADPKD Patients with Pneumonia

International Journal of Nephrology, 2011
Background. In animal models, polycystic kidneys are susceptible to acute kidney injury (AKI). We examined the occurrence of AKI in a cohort of autosomal dominant polycystic kidney disease (ADPKD) and non-ADPKD patients with acute pneumonia. Design.
Carlos Franco Palacios, Mira T. Keddis, Dingxin Qin, Ladan Zand, Guangxi Li, Xiangling Wang, Rodrigo Cartin-Ceba, Robert P. Hartman, Qi Qian   +8 more
doaj   +1 more source

Unilateral autosomal dominant polycystic kidney disease with co-existent renal cell carcinoma: A rare entity

The Egyptian Journal of Radiology and Nuclear Medicine, 2018
Bilateral ADPKD is a well-known entity, but there are only a few reports on unilateral ADPKD in adults, most of which had associated contralateral agenesis. Further rare is the development of RCC in unilateral ADPKD.
Anupama Tandon, Mohd Shuaib Qureshi, Irfan Ahmad, Usha Rani Singh, Shuchi Bhatt   +4 more
doaj   +1 more source

Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease

Canadian Journal of Kidney Health and Disease, 2017
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder worldwide. The disease is characterized by renal cysts and progressive renal failure due to progressive enlargement of cysts and renal fibrosis. An estimated
Steven Soroka, Ahsan Alam, Micheli Bevilacqua, Louis-Philippe Girard, Paul Komenda, Rolf Loertscher, Philip McFarlane, Sanjaya Pandeya, Paul Tam, Daniel G. Bichet   +9 more
doaj   +1 more source

SNX9 Inhibits Cell Proliferation and Cyst Development in Autosomal Dominant Polycystic Kidney Disease via Activation of the Hippo-YAP Signaling Pathway

Frontiers in Cell and Developmental Biology, 2020
Autosomal dominant polycystic kidney disease (ADPKD) is a complex process, involving the alteration of multiple genes and signaling pathways, and the pathogenesis of ADPKD remains largely unknown.
Ai-Wen Shen, Li-Li Fu, Lu Lin, Bo Sun, Dong-Xu Song, Wu-Tao Wang, Yi-Hao Wang, Pei-Ran Yin, Sheng-Qiang Yu   +8 more
doaj   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, EarlyView.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.

American Journal of Kidney Diseases, 2019
RATIONALE & OBJECTIVE The vasopressin V2 receptor antagonist (V2RA) tolvaptan is the first drug that has been shown to slow the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD).
B. Kramers, M. V. van Gastel, W. Boertien, E. Meijer, R. Gansevoort   +4 more
semanticscholar   +1 more source